Your shopping cart is currently empty

Atpenin A5 is a potent and highly specific complex II inhibitor (IC50 ~10 nM), as well as an effective mKATP channel agonist and cardioprotective agent [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $255 | In Stock | In Stock | |
| 2 mg | $346 | In Stock | In Stock | |
| 5 mg | $522 | In Stock | In Stock | |
| 10 mg | $759 | In Stock | In Stock | |
| 25 mg | $1,170 | In Stock | In Stock | |
| 50 mg | $1,580 | - | In Stock |
| Description | Atpenin A5 is a potent and highly specific complex II inhibitor (IC50 ~10 nM), as well as an effective mKATP channel agonist and cardioprotective agent [1]. |
| In vitro | Atpenin A5 effectively inhibits submitochondrial particles (SMPs), mitochondria, and cardiomyocytes, exhibiting IC50 values of 8.3 nM, 9.3 nM, and 8.5 nM, respectively. It acts as a potent, specific inhibitor of complex II. Moreover, at a concentration of 1 nM, Atpenin A5 (AA5) activates the mitochondrial ATP-sensitive potassium (mKATP) channel and offers protection against simulated ischemia-reperfusion (IR) injury in isolated cardiomyocytes[1]. |
| In vivo | Atpenin A5, a potent succinate dehydrogenase (SDH) inhibitor, promotes cardiomyocyte mitosis and regeneration in the postnatal heart following myocardial infarction (MI). Mice injected with Atpenin A5 (100 μg/kg) showed increased myocardial thickness at the infarct zone and a significant reduction in scar size compared with controls[2]. |
| Molecular Weight | 366.24 |
| Formula | C15H21Cl2NO5 |
| Cas No. | 119509-24-9 |
| Smiles | COc1[nH]c(=O)c(C(=O)[C@@H](C)C[C@H](C)[C@@H](Cl)CCl)c(O)c1OC |
| Relative Density. | 1.31g/cm3 |
| Storage | store at low temperature,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (273.04 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (10.92 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.